New guidelines recommend chemoprevention (tamoxifen or raloxifene) for high-risk patients.
Women are underrepresented and gender-specific analysis is uncommon in most clinical trials.
It has been suggested that physicians may be misdiagnosing women more often because their symptoms may differ from those experienced by men.
In this innovative practice model, pharmacists collaborate with women's health providers to educate patients.
Surgical techniques are directed at decreasing pain, discomfort, and complications.